Exagen Announces Acceptance of Six Abstracts at 2025 American College of Rheumatology Convergence
Exagen (Nasdaq: XGN) announced acceptance of six abstracts for ACR Convergence 2025, held Oct 24–29, 2025 in Chicago. The program includes a plenary presentation on Oct 27 highlighting a urinary tenascin C panel that may predict kidney function loss in lupus nephritis and several posters on anti-RA33, anti-PAD4, T cell biomarkers, a kidney-specific four-protein index, and a multianalyte lupus risk score to improve AVISE CTD diagnostic precision.
Exagen will host an Innovation Theater on Oct 27, 2:30–3:15pm CDT and staff the booth #1228 for follow-up.
Exagen (Nasdaq: XGN) ha annunciato l'accettazione di sei abstract per ACR Convergence 2025, che si svolgerà dal 24 al 29 ottobre 2025 a Chicago. Il programma include una presentazione plenaria il 27 ottobre che mette in evidenza un pannello di tenascin C urinaria che potrebbe predire la perdita della funzione renale nella lupus nephritis e diversi poster su anti-RA33, anti-PAD4, biomarcatori delle cellule T, un indice renale specifico a quattro proteine e un punteggio di rischio multianalitico per il lupus per migliorare la precisione diagnostica di AVISE CTD. Exagen ospiterà un Innovation Theater il 27 ottobre dalle 14:30 alle 15:15 CDT e assisterà lo stand #1228 per follow-up.
Exagen (Nasdaq: XGN) anunció la aceptación de seis abstracts para ACR Convergence 2025, que se celebra del 24 al 29 de octubre de 2025 en Chicago. El programa incluye una presentación plenaria el 27 de octubre que destaca un panel urinario de tenascin C que podría predecir la pérdida de función renal en la nefritis lúpica y varios pósteres sobre anti-RA33, anti-PAD4, biomarcadores de células T, un índice renal específico de cuatro proteínas y un puntaje de riesgo multianalítico del lupus para mejorar la precisión diagnóstica de AVISE CTD. Exagen organizará un Innovation Theater el 27 de octubre, de 2:30 a 3:15 p.m. CDT, y atenderá al stand #1228 para seguimiento.
Exagen (Nasdaq: XGN)은 2025년 10월 24일부터 29일까지 시카고에서 개최되는 ACR Convergence 2025를 위한 여섯 편의 초록 채택을 발표했습니다. 프로그램에는 10월 27일 기조 발표가 포함되며, 신장 기능 손실을 예측할 수 있는 루푸스 신염의 소변 텐아신 C 패널을 강조하고 anti-RA33, anti-PAD4, T세포 바이오마커, 신장 특이 네 단백질 지수, 다중 분석 루푸스 위험 점수에 관한 여러 포스터가 AVISE CTD 진단 정확도를 개선합니다.
Exagen은 10월 27일 2:30–3:15pm CDT에 Innovation Theater를 주최하고, 부스 #1228에서 후속 조치를 진행합니다.
Exagen (Nasdaq: XGN) a annoncé l'acceptation de six résumés pour l’ACR Convergence 2025, qui se tient du 24 au 29 octobre 2025 à Chicago. Le programme comprend une présentation plénière le 27 octobre mettant en évidence un panel urinaire de tenascine C qui pourrait prédire la perte de fonction rénale dans le lupus néphrite et plusieurs affiches sur anti-RA33, anti-PAD4, des biomarqueurs des cellules T, un indice rénal spécifique à quatre protéines et un score de risque du lupus multianalytique pour améliorer la précision diagnostique d’AVISE CTD. Exagen animera un Innovation Theater le 27 octobre, de 14h30 à 15h15 CDT, et tiendra le stand #1228 pour le suivi.
Exagen (Nasdaq: XGN) gab die Annahme von sechs Abstracts für die ACR Convergence 2025 bekannt, die vom 24. bis 29. Oktober 2025 in Chicago stattfindet. Das Programm beinhaltet eine Plenarvorlesung am 27. Oktober, die auf ein Urin-Tenascin-C-Panel hinweist, das einen Funktionsverlust der Nieren bei Lupus nephritis vorhersagen könnte, und mehrere Poster zu Anti-RA33, Anti-PAD4, T-Zell-Biomarkern, einen nierenspezifischen Vier-Protein-Indikator und einen multi-Analyte-Lupus-Risiko-Score zur Verbesserung der diagnostischen Präzision von AVISE CTD. Exagen wird am 27. Oktober von 14:30–15:15 Uhr CDT ein Innovation Theater ausrichten und den Stand #1228 für Nachverfolgung betreiben.
Exagen (ناسداك: XGN) أعلنت قبول ستة ملخصات للاجتماع ACR Convergence 2025، الذي يعقد في شيكاغو من 24 إلى 29 أكتوبر 2025. يتضمن البرنامج عرضاً افتتاحياً في 27 أكتوبر يسلّط الضوء على لوحة Tenascin C البولية قد تتنبأ بفقدان وظيفة الكلى في الذئبة الكلوية، وكذلك عدة عروض وبائية حول anti-RA33، anti-PAD4، علامات حيوية لخلايا T، ومؤشر رباعي البروتين Kidney-specific، ونطاق مخاطر Lupus متعدد التحاليل لتحسين دقة تشخيص AVISE CTD. ستستضيف Exagen Innovation Theater في 27 أكتوبر من الساعة 2:30 إلى 3:15 مساءً بتوقيت CDT وستدير الجناح #1228 للمتابعة.
Exagen（纳斯达克代码：XGN）宣布接受六篇摘要用于ACR Convergence 2025，该会议于 2025 年 10 月 24 日至 10 月 29 日在芝加哥举行。该项目包括在 10 月 27 日的 全体会议演讲，重点介绍一组尿液中的 Tenascin C 面板，可能预测狼疮性肾炎的肾功能丧失，以及关于 anti-RA33、anti-PAD4、T 细胞生物标志物、四蛋白肾脏特异指数和多分析物狼疮风险评分的多篇海报，以提升 AVISE CTD 的诊断准确性。Exagen 将于 10 月 27 日举行 创新演讲厅（Innovation Theater），时间为 CDT 下午 2:30–3:15，并在展位 #1228 进行后续跟进。
- None.
- None.
CARLSBAD, Calif., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, announced today the acceptance of six abstracts at the 2025 American College of Rheumatology’s (ACR) annual meeting, ACR Convergence 2025, being held October 24-29, 2025, at the McCormick Place Convention Center in Chicago, Illinois.
Exagen’s featured plenary presentation, in collaboration with Johns Hopkins University, will highlight a urinary biomarker panel that holds the potential to guide precision management of Lupus Nephritis, addressing a critical need for rheumatologists. Additional abstracts highlight Exagen’s innovative research on harnessing anti-RA33, anti-PAD4, and traditional biomarkers to enhance RA diagnostic accuracy, and T Cell biomarkers to differentiate systemic lupus erythematosus (SLE) from other conditions, both of which will elevate AVISE® CTD’s overall diagnostic precision.
“I’m excited to share and discuss our latest data on novel approaches to improve patient care in autoimmunity during this year’s ACR meeting. Alongside our expansion of precision medicine solutions in SLE, more specifically for patients suffering from lupus nephritis, we’ll highlight our progress in rheumatoid arthritis, which aligns with the recent launch of anti-PAD4 antibodies, as the first and only laboratory offering this innovative biomarker,” said Michael Mahler, PhD, Chief Scientific Officer of Exagen. “For the first time, we’ll also present preliminary data on a novel kidney damage biomarker panel that has the potential to transform how early kidney disease is managed.”
On Monday, Oct 27, 2025 from 2:30-3:15pm CDT, Exagen will be hosting an Innovation Theater featuring both Alvin Wells, MD, PhD, FACP, FACR and Vasileios Kyttaris, MD, PhD, FACR on AVISE CTD: A Decade of Validation Driving Lupus Diagnostic Accuracy, Seronegative RA Biomarker Innovation, and Novel T Cell Biomarkers for Lupus. Exagen will be at booth #1228 for follow-up questions and continued conversation.
Below is the list of accepted abstracts, with links to each:
Plenary Talk: Monday, October 27, 2025
Plenary Presentation | Presented by Andrea Fava | Abstract #2129388
Title: Urinary Tenascin C Predicts Kidney Function Loss in Lupus Nephritis
Session: Plenary II
Session Time: 8:30am – 8:45am CT
Sunday, October 26, 2025
Poster Presentation | Presented by Vasileios Kyttaris | Abstract #2128441
Title: A Machine Learning Classifier Leveraging Anti-RA33, Anti-PAD4, and Conventional Biomarkers Enhances Diagnostic Performance Characteristics for RA
Session: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster I
Session Time: 10:30am – 12:30pm CT
Poster Presentation | Presented by Sepehr Taghavi | Abstract #2128477
Title: A Novel Kidney-Specific Biomarker Panel Accurately Differentiates Lupus Nephritis from Diabetic Kidney Disease through Distinct Molecular Pathways
Session: Systemic Lupus Erythematosus–Diagnosis, Manifestations, & Outcomes Poster I
Session Time: 10:30am – 12:30pm CT
Tuesday, October 28, 2025
Poster Presentation | Presented by Sepehr Taghavi | Abstract #2128438
Title: Kidney-Specific Four-Protein Index Outperforms Conventional Measures for Detecting Early Kidney Damage in Lupus Nephritis and Diabetic Kidney Disease
Session: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
Session Time: 10:30am – 12:30pm CT
Poster Presentation | Presented by Vasileios Kyttaris | Abstract #2128433
Title: Specificity of Cell-bound T Cell Biomarkers (TC4d, TIgG, TIgM) in Differentiating SLE from ANA-Associated Rheumatic Diseases
Session: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
Session Time: 10:30am – 12:30pm CT
Poster Presentation | Presented by Vasileios Kyttaris | Abstract #2128444
Title: The Clinical Utility of a Multianalyte Lupus Risk Score Incorporating Cell-bound Complement Activation Products: A Systematic Evaluation
Session: Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster III
Session Time: 10:30am – 12:30pm CT
About Exagen Inc.
Exagen Inc. (Nasdaq: XGN) is a leading provider of autoimmune diagnostics, committed to transforming care for patients with chronic and debilitating autoimmune conditions. Based in San Diego County, California, Exagen’s mission is to provide clarity in autoimmune disease decision-making and improve clinical outcomes through its innovative testing portfolio. The company’s flagship product, AVISE® CTD, enables clinicians to more effectively diagnose complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren’s disease earlier and with greater accuracy. Exagen’s CLIA-certified, CAP-accredited laboratory specializes in the testing of rheumatic diseases, delivering precise and timely results, supported by a suite of AVISE-branded tests for disease diagnosis, prognosis, and monitoring. With a focus on research, innovation, education, and patient-centered care, Exagen is dedicated to addressing the ongoing challenges of autoimmune disease management.
For more information, visit Exagen.com or follow Exagen on LinkedIn.
Forward Looking Statements
Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Exagen's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation Exagen’s goals, strategies and ambitions; potential future financial and business performance; the potential for Exagen’s research to lead to positive impacts to patients; the potential for Exagen’s research to lead to new or improved testing products, including a urinary biomarker panel for the management of Lupus Nephritis and a novel kidney damage biomarker panel; the potential utility and effectiveness of Exagen’s services and testing solutions; updates made to AVISE® CTD, including SLE and RA biomarkers; potential shareholder value and growth and 2024 guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and in interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; changes in laws and regulations related to Exagen’s regulatory requirements; Exagen’s commercial success depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s prior press releases and Exagen’s filings with the Securities and Exchange Commission (“SEC”), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2024 and any subsequent filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Contact:
Ryan Douglas
Exagen Inc.
ir@exagen.com
760.560.1525
FAQ
What did Exagen (XGN) announce for ACR Convergence 2025?
When and where is Exagen presenting its plenary talk at ACR Convergence 2025?
What time is Exagen’s Innovation Theater at ACR Convergence 2025 and who is presenting?
Which Exagen abstracts address lupus nephritis biomarkers at ACR Convergence 2025?
How can attendees follow up with Exagen (XGN) at ACR Convergence 2025?
